会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明申请
    • Encrypted-traffic discrimination device and encrypted-traffic discrimination system
    • 加密流量识别装置和加密流量辨别系统
    • US20100223455A1
    • 2010-09-02
    • US12659069
    • 2010-02-24
    • Shingo AtaGo HasegawaYoshihiro NakahiraNobuyuki Nakamura
    • Shingo AtaGo HasegawaYoshihiro NakahiraNobuyuki Nakamura
    • H04L9/00
    • H04L63/0428H04L47/2441
    • An encrypted-traffic discrimination device includes an input interface, a flow discrimination section, a data accumulation section, a selective data calculation section, a calculation result determination section, and an output interface. The flow discrimination section discriminates the input traffic into separate flows based on at least a transmission origin address and a transmission destination address. The data accumulation section accumulates characteristic amount data of the traffic for each of the separate flows. The selective data calculation section executes an evaluation computation utilizing specific data from the characteristic amount data. The calculation result determination section that, based on a calculated evaluation computation value, executes threshold value determination to determine whether or not the traffic is encrypted, and, if the traffic is determined to be encrypted, which encryption format the traffic is encrypted with.
    • 加密流量判别装置包括输入接口,流量鉴别部,数据存储部,选择性数据计算部,计算结果判定部,输出接口。 流检测部分至少基于发送源地址和发送目的地地址将输入业务区分为单独的流。 数据累积部累积各流量的流量的特征量数据。 选择性数据计算部使用来自特征量数据的特定数据来执行评价计算。 计算结果确定部,其基于计算出的评价运算值,执行阈值判定,判定是否加密了业务,并且,如果确定要加密的业务,则加密业务的加密格式。
    • 17. 发明授权
    • Abnormality detection system, abnormality management apparatus, abnormality management method, probe and program
    • 异常检测系统,异常管理装置,异常管理方法,探头和程序
    • US07594014B2
    • 2009-09-22
    • US11498809
    • 2006-08-04
    • Nobuyuki Nakamura
    • Nobuyuki Nakamura
    • G06F15/173
    • H04L1/24
    • An abnormality management apparatus, connected via a network to a plurality of probes disposed at arbitrary positions in the network, comprises an abnormality level reception unit that receives information indicating an abnormality level calculated at each of the plurality of probes, an abnormality analysis unit that judges the scale of an abnormality manifesting in the network based upon an average value of the abnormality levels indicated at the plurality of probes and deviations relative to the average value and a result output unit that outputs results obtained at the abnormality analysis unit. The structure enables accurate assessment of the scale of an abnormality having occurred in the network and quick response to the abnormality by detecting its cause at an early stage.
    • 一种异常管理装置,通过网络连接到布置在网络中的任意位置的多个探头,包括异常等级接收单元,其接收指示在多个探针中的每一个处计算出的异常水平的信息,异常分析单元,其判断 基于在多个探测器中指示的异常水平的平均值和相对于平均值的偏差在网络中显示的异常的比例,以及输出在异常分析单元获得的结果的结果输出单元。 该结构能够准确地评估网络中发生的异常的规模,并通过早期检测其原因对异常进行快速响应。
    • 18. 发明申请
    • Ultra soft high carbon hot-rolled steel sheets and manufacturing method thereof
    • 超软高碳热轧钢板及其制造方法
    • US20090065106A1
    • 2009-03-12
    • US11919964
    • 2006-09-19
    • Hideyuki KimuraTakeshi FujitaNobuyuki NakamuraSatoshi UeokaNaoya AokiKenichi Mitsuzuka
    • Hideyuki KimuraTakeshi FujitaNobuyuki NakamuraSatoshi UeokaNaoya AokiKenichi Mitsuzuka
    • C21D8/02C22C38/00C21D6/02
    • C22C38/02C21D1/32C21D6/008C21D8/0263C21D9/46C22C38/04C22C38/12C22C38/14C22C38/18C22C38/32
    • The present invention provides an ultra soft high carbon hot-rolled steel sheet. The ultra soft high carbon hot-rolled steel sheet contains 0.2% to 0.7% of C, 0.01% to 1.0% of Si, 0.1% to 1.0% of Mn, 0.03% or less of P, 0.035% or less of S, 0.08% or less of Al, 0.01% or less of N, and the balance being Fe and incidental impurities and further contains 0.0010% to 0.0050% of B and 0.05% to 0.30% of Cr in some cases. In the texture of the steel sheet, an average ferrite grain diameter is 20 μm or more, a volume ratio of ferrite grains having a grain diameter of 10 μm or more is 80% or more, and an average carbide grain diameter is in the range of 0.10 to less than 2.0 μm. In addition, the steel sheet is manufactured by the steps, after rough rolling, performing finish rolling at a reduction ratio of 10% or more and at a finish temperature of (Ar3−20° C.) or more in a final pass, then performing first cooling within 2 seconds after the finish rolling to a cooling stop temperature of 600° C. or less at a cooling rate of more than 120° C./sec, then performing second cooling so that the steel thus processed is held at 600° C. or less, then performing coiling at 580° C. or less, followed by pickling, and then performing spheroidizing annealing at a temperature in the range of 680° C. to the Ac1 transformation point.
    • 本发明提供一种超软质高碳热轧钢板。 超软质高碳热轧钢板含有C:0.2〜0.7%,Si:0.01〜1.0%,Mn:0.1〜1.0%,P:0.03%以下,S:0.035%以下,0.08以下 Al以下,Al:0.01%以下,余量为Fe和附带杂质,在某些情况下还含有0.0010〜0.0050%的B和0.05〜0.30%的Cr。 在钢板的织构中,平均铁素体晶粒直径为20μm以上,粒径为10μm以上的铁素体晶粒的体积比为80%以上,平均碳化物粒径为 为0.10〜小于2.0μm。 另外,在粗轧后,在最终通过时以10%以上的还原率和最终温度(Ar 3〜20℃)以上的精轧进行精轧,然后, 在精轧后2秒内进行冷却至冷却停止温度600℃以下,冷却速度大于120℃/秒,然后进行第二次冷却,使被处理钢被保持在600℃ ℃以下,然后在580℃以下进行卷取,然后酸洗,然后在680℃的温度下进行Ac1相变点的球化退火。
    • 20. 发明申请
    • Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
    • 包含与活性成分相同的托烷化合物和药物组合物
    • US20080027094A1
    • 2008-01-31
    • US11661310
    • 2005-08-29
    • Hisao NakaiToshihiko NishiyamaNobuyuki NakamuraManabu Fujita
    • Hisao NakaiToshihiko NishiyamaNobuyuki NakamuraManabu Fujita
    • A61K31/46A61P11/06C07D451/02
    • C07D451/06A61K31/00
    • The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X− is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
    • 通过吸入给药的常规抗胆碱能药物被认为具有加重与血液介导的前列腺增生相关的排尿困难的可能性,并且已经要求用于通过吸入给药的常规抗胆碱能药物必须显示减少的副作用或不良反应 。 本发明涉及由通式(I)表示的化合物:(其中A表示; R 1,R 2,R 3, 和R 1各自为氢原子或取代基; R 5为取代基; X为 - 阴离子;符号为:img id =“custom-character-00001”he =“2.46mm”wi =“3.89mm”file =“US20080027094A1-20080131-P00001.TIF”img-content =“character”img-format =“tif”/> 外部形式或内在形式,或其混合物),其盐或溶剂化产物。 它们可用作对由毒蕈碱受体介导的疾病的副作用或不良反应降低的预防和/或治疗剂。